Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Media Resources
2016
Civil Society Urges Member States to Support the Dutch EU Presidency’s Vision on Access to Affordable Medicines
Assessing EU Funding for R&D for Poverty-related and Neglected Diseases
HAI Intervention at the United Nations High-Level Panel on Access to Medicines
Access to High-priced Medicines in Hospital Settings in Europe: A Study in Four European Countries
Study Finds Access to High-priced Medicines May Differ Across EU
Why You Should Be Concerned About TTIP and Access to Medicines
European CSOs Call for Rejection of EU Trade Secrets Directive
2015
Trilogue Negotiations on Commission’s Proposal for Trade Secrets Directive
Medicines Transparency Alliance (MeTA) Evaluation
Global Snakebite Initiative Appoints Health Action International as Secretariat
Multi-sectoral NGO Coalition Calls on Parliament to Defend Safeguards for Consumers, Journalists, Whistleblowers, Public Authorities and Workers
Empty Gestures – The EU’s Commitments to Safeguard Access to Medicines
HAI and MSF Report Shows European Commission’s Access to Medicines Commitments are ‘Empty Gestures’
EU medicines policy & access to medicines
Early Access to Medicines Marketing Authorisation Flexibilities Should Only Respond to Unmet Medical Needs, Must Protect Patient Safety
Direct Patient Reporting in the EU: A Snapshot of Reporting Systems in Seven Member States
Declaration of Public Interest Regarding Access to Imatinib (Glivec) in Colombia
Health Action International Opposes European Parliament’s ISDS Compromise in TTIP
EU Medicines Policy and Access to Medicines
HAI Sexual Harassment Policy
Health Action International Launches New Brussels Office
Health Action International Criticises JURI Support for EU Trade Secrets Directive Report
How TTIP Could Damage Access to Affordable Medicines in the European Union
Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion
2014 Annual Report and Financial Statements
2014 Annual Report and Financial Statements
EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions
2014